Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis. Keystone, E. C., Taylor, P. C., Genovese, M. C., Schlichting, D. E., De La Torre, I., Beattie, S. D., Rooney, T. WILEY-BLACKWELL. 2014: S1232

View details for Web of Science ID 000344384906057